{
    "clinical_study": {
        "@rank": "21551", 
        "arm_group": [
            {
                "arm_group_label": "Single dose group", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Multiple dose group", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "To evaluate the safety and plasma concentration change of YM178 after single- and\n      repeated-administration as oral absorption controlled tablet in healthy Chinese subjects."
        }, 
        "brief_title": "Study to Assess the Safety and Plasma Concentration of YM178 OCAS Tablet (Mirabegron) in Healthy Chinese Volunteers", 
        "completion_date": {
            "#text": "August 2012", 
            "@type": "Actual"
        }, 
        "condition": "Healthy Chinese Volunteers", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Body Mass Index (BMI) between 19 and 24, the weight is no less than 50 kg.\n\n          2. Good health status\n\n          3. The female subject must be either post-menopausal or surgically sterile. All women of\n             child bearing potential will be required to use adequate contraception, must not be\n             lactating, and must not be breastfeeding.\n\n        Exclusion Criteria:\n\n          1. The subject who has a known or suspected hypersensitivity to test drug or any of the\n             constituents of the formulation used.\n\n          2. Drug abusers and alcoholics.\n\n          3. The subject who has consumed alcohol within 36 hours before administration.\n\n          4. The subject who is positive for hepatitis B surface antigen (HBs- Ag) or hepatitis C\n             virus (HCV) antibody.\n\n          5. The subject who is positive for human immunodeficiency virus (HIV).\n\n          6. The subject who consumes more than 1L tea and coffee per day.\n\n          7. Smokers.\n\n          8. The subject who has donated or lost over 200 mL blood\n\n          9. The subject who has participated in other clinical trials\n\n         10. The subject who has taken other drugs that prototype and its main metabolites had not\n             completely eliminated\n\n         11. The subject who has taken drugs repeatedly that may affect the metabolism of the test\n             drug\n\n         12. Psychopath."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "40 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 31, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01720212", 
            "org_study_id": "178-CL-091"
        }, 
        "intervention": {
            "arm_group_label": [
                "Single dose group", 
                "Multiple dose group"
            ], 
            "description": "oral", 
            "intervention_name": "YM178", 
            "intervention_type": "Drug", 
            "other_name": "Mirabegron"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "YM178", 
            "Mirabegron", 
            "OCAS", 
            "Chinese Healthy Volunteers", 
            "PK", 
            "Safety"
        ], 
        "lastchanged_date": "October 31, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Shanghai", 
                    "country": "China"
                }
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "An Open-Label, Single and Multiple Dose Study to Assess the Safety and Pharmacokinetics of YM178 OCAS Tablet (Mirabegron) in Healthy Chinese Volunteers", 
        "overall_official": {
            "affiliation": "Astellas Pharma Inc", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "AUC of YM178 assessed by the plasma concentration changes", 
                "safety_issue": "No", 
                "time_frame": "Up to 96 hours after administration"
            }, 
            {
                "measure": "Cmax of YM178 assessed by the plasma concentration changes", 
                "safety_issue": "No", 
                "time_frame": "Up to 96 hours after administration"
            }, 
            {
                "measure": "t1/2 of YM178 assessed by the plasma concentration changes", 
                "safety_issue": "No", 
                "time_frame": "Up to 96 hours after administration"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01720212"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Safety is to be assessed by the incidence of adverse events, vital signs, lab-tests and 12-lead ECGs", 
            "measure": "Safety assessment of YM178", 
            "safety_issue": "No", 
            "time_frame": "Up to 33 days"
        }, 
        "source": "Astellas Pharma Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Astellas Pharma China, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "October 2012"
    }
}